A Phase 2 Study of EIK1001 in Combo With Pembrolizumab and Chemotherapy in Patients With Stage 4 NSCLC
Clinical trial NCT06246110 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT06246110
- Sponsor
- Eikon Therapeutics
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2024-02-06
- Primary completion
- 2026-12-01
- Enrollment
- 70
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.